Metagenomi Therapeutics, Inc. Stock: price and insider trades · United States

Every trade that managers of Metagenomi Therapeutics, Inc. disclose to SEC (Form 4) is tracked on this page. The company sits in the Health Care sector. The last twelve months, up to 24 October 2026, brought 24 filings signed by 5 insiders.

Purchases and sales both appear in the filings: 2 purchases (1 insider, €20k) and 14 sales (4 insiders, €30k). Sales outweigh purchases by €9,725. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. The largest single trade was a purchase of €20k by Reid Laurence, published on 11 September 2026, equal to 0.076% of the market capitalisation. The buyers include 1 senior executive.

The most recent open-market purchase was published on 11 September 2026, 43 days ago. The median gap between a trade and its publication by SEC (Form 4) is 3 days. US insiders must file a Form 4 within two business days of a trade. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives.

Across the 3,167 companies tracked on its exchange, the median is 24 filings; at 24 filings, this issuer sits right on that mark. Since 2024, the database holds 4 purchases and 23 sales by insiders of the company. In its latest annual report filed with the SEC (10-K, fiscal year ended 31 December 2025), the company reported revenue of 25.2 m USD and net income of -87.9 m USD.

Elsewhere in the same sector, our signals recently picked up insider purchases at Dynavox Group AB and EssilorLuxottica. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.